Multiple System Atrophy clinical trials

Explore recruiting multiple system atrophy clinical trials.

Recruiting multiple system atrophy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Multiple System Atrophy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy

Denmark, Spain, Austria, France, Germany, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients with Multiple System Atrophy (TOPAS-MSA)

Spain, France, Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

France, Portugal, Austria, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Interventional, randomized, double-blind, placebo-controlled, optional open-label extension trial of Lu AF82422 in participants with Multiple System Atrophy

Germany, Spain, Italy, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

(ASK-PD0-CS002) Long-Term Safety and Efficacy Follow-up of AB-1005 Gene Transfer Study Participants with Parkinson’s Disease or Multiple System Atrophy

Poland

Therapeutic use (Phase IV) EU CTIS Study details

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy

Denmark, Italy, Portugal, Spain, Germany, France +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Multiple System Atrophy trials by city

Multiple System Atrophy in Toronto Multiple System Atrophy in Vancouver Multiple System Atrophy in Montreal Multiple System Atrophy in Calgary Multiple System Atrophy in Edmonton Multiple System Atrophy in Ottawa Multiple System Atrophy in Winnipeg Multiple System Atrophy in Quebec City Multiple System Atrophy in Hamilton Multiple System Atrophy in Kitchener Multiple System Atrophy in London Multiple System Atrophy in Halifax Multiple System Atrophy in New York Multiple System Atrophy in Los Angeles Multiple System Atrophy in Chicago Multiple System Atrophy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease